[ad_1]
The first result of the Phase 3 experiments of the Chinese Sinovac coronavirus vaccine came from Indonesia, one of the countries where the experiments were conducted.
Bio Farma, the pharmaceutical agency affiliated with the Indonesian state, announced that the vaccine provided 97 percent protection, according to early results.
1,600 people participated in clinical trials of the Sinovac vaccine in Indonesia. The Bio Farma spokesperson did not explain how many of these 1,600 people were infected during the vaccination studies. The spokesperson said they expect the vaccine to be approved for emergency use in Indonesia by the end of January.
IT WILL BE ANNOUNCED IN BRAZIL ON DECEMBER 15
The results announced by Indonesia are the first announced results of phase 3 trials of the vaccine. In Brazil, one of the countries where phase 3 trials of the Sinovac vaccine were conducted, the results are expected to be announced on December 15.
The Beijing-based Sinovac spokesperson stated that they have no efficacy data for the vaccine and that efficacy data is expected from Brazilian trials.
Sinovac’s phase 3 trials, including Indonesia, had been conducted in a group of countries that were also Brazil and Turkey.
Health Minister Fahrettin Koca, Turkey, the vaccine produced by Sinovac China announced that it had ordered 50 million doses.
IT CAN BE DONE FROM DECEMBER 25 TO 26
On the other hand, the Director General of the World Health Organization (WHO), Dr. Tedros Adhanom Ghebreyesus affirmed that countries will introduce new types of vaccines against the coronavirus (Covid-19) in the coming weeks and months, and requested the vaccination of those most in need at the beginning, following the guidelines prepared by the WHO.
Member of the Coronavirus Scientific Committee of the Ministry of Health Prof. Dr. Fire Land, scheduled to arrive in Turkey on December 11-19 Covidien of the first application, the need for at least 14 days for testing, said it could be done from the December 25 to 26.
